Dyslipidemia is a major cardiovascular risk factor. While dietary phytosterols are known to lower cholesterol, the mechanisms involving the gut-liver axis are not fully understood. By integrating human clinical trials and mechanistic animal models, we demonstrate that phytosterols improve lipid p...

This study investigated the regulatory effects of three probiotics (P. pentosaceus, B. coagulans, and E. faecalis) on bile acid metabolism in common carp (Cyprinus carpio) fed a high-carbohydrate-high-fat (HCHF) diet for 56 days. A targeted metabolomics approach using UHPLC-QTRAP-MS/MS with sched...

The co-occurrence of gut microbiota dysbiosis and bile acids (BAs) metabolism alteration has been reported in several human liver diseases. However, the gut microbiota dysbiosis in infantile cholestatic jaundice (CJ), and the linkage between gut bacterial changes and alterations of BAs metabolism...

Dyslipidemia is a major cardiovascular risk factor. While dietary phytosterols are known to lower cholesterol, the mechanisms involving the gut-liver axis are not fully understood. By integrating human clinical trials and mechanistic animal models, we demonstrate that phytosterols improve lipid p...

Dyslipidemia is a major cardiovascular risk factor. While dietary phytosterols are known to lower cholesterol, the mechanisms involving the gut-liver axis are not fully understood. By integrating human clinical trials and mechanistic animal models, we demonstrate that phytosterols improve lipid p...

Dyslipidemia is a major cardiovascular risk factor. While dietary phytosterols are known to lower cholesterol, the mechanisms involving the gut-liver axis are not fully understood. By integrating human clinical trials and mechanistic animal models, we demonstrate that phytosterols improve lipid p...